Comparative Pharmacology
Head-to-head clinical analysis: DUO MEDIHALER versus GLYCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUO MEDIHALER versus GLYCORT.
DUO-MEDIHALER vs GLYCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone propionate, a corticosteroid with anti-inflammatory activity, and salmeterol, a long-acting beta2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle by stimulating intracellular adenyl cyclase, increasing cyclic AMP levels.
Glucocorticoid receptor agonist; modulates gene expression to produce anti-inflammatory and immunosuppressive effects.
Two inhalations (50 mcg ipratropium bromide and 100 mcg fenoterol hydrobromide per inhalation) four times daily via metered-dose inhaler.
Intravenous: 2 mg/kg every 12 hours; Oral: 20 mg twice daily.
None Documented
None Documented
Terminal elimination half-life of 3-4 hours for the bronchodilator component and 6-8 hours for the corticosteroid component; clinically requires twice-daily dosing.
3.5 hours (terminal); prolonged in hepatic impairment (up to 8 hours) and severe renal impairment (up to 6 hours)
Renal: 70-80% (free drug and metabolites), Biliary/Fecal: 10-20%
Renal: 70% as unchanged drug; biliary/fecal: 25% (metabolites); 5% other
Category C
Category C
Anticholinergic/Beta2-Agonist Combination
Anticholinergic